BBT Capital Management’s Tempest Therapeutics TPST Stock Holding History

BBT Capital Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-87	Closed	-$355K	–	82
2017 Q4	$355K	Hold	87	–	–	0.07%	67
2017 Q3	$360K	Hold	87	–	–	0.05%	84
2017 Q2	$396K	Hold	87	–	–	0.05%	92
2017 Q1	$474K	Hold	87	–	–	0.08%	79
2016 Q4	$388K	Hold	87	–	–	0.08%	77
2016 Q3	$1.82M	Hold	87	–	–	0.35%	69
2016 Q2	$1.32M	Hold	87	–	–	0.21%	79
2016 Q1	$2.41M	Sell	87 -58	-40%	-$1.23M	0.47%	52
2015 Q4	$4.13M	Hold	145	–	–	0.49%	54
2015 Q3	$3.59M	Hold	145	–	–	0.33%	81
2015 Q2	$12.2M	Hold	145	–	–	1.12%	28
2015 Q1	$14.7M	Hold	145	–	–	1.5%	18
2014 Q4	$18.7M	Hold	145	–	–	1.56%	12
2014 Q3	$7.02M	Hold	145	–	–	0.38%	73
2014 Q2	$3.88M	Hold	145	–	–	0.24%	108
2014 Q1	$3.78M	Sell	145 -28	-16%	-$794K	0.17%	151
2013 Q4	$4.63M	Sell	173 -8	-4%	-$219K	0.21%	117
2013 Q3	$5.25M	Sell	181 -47	-21%	-$1.67M	0.27%	89
2013 Q2	$9.17M	Buy	+228	New	+$8.57M	0.49%	60

Other funds holding TPST

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BBT Capital Management's TPST Position: Q1 2018 in Review

BBT Capital Management sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 87 shares — an estimated $355K sold.

BBT Capital Management first reported a position in TPST in Q2 2013 and held it in 19 quarters. The position peaked at $18.7M in Q4 2014. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

BBT Capital Management reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
BBT Capital Management sold 87 Tempest Therapeutics shares in Q1 2018, an estimated $355K.
BBT Capital Management first reported a position in Tempest Therapeutics in Q2 2013 and held it in 19 quarters.
BBT Capital Management's Tempest Therapeutics position peaked at $18.7M in Q4 2014.
41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on BBT Capital Management's 13F filing for Q1 2018, filed 11 May 2018.